Senti Biosciences Holdings, Inc. filed an amendment to its Amended and Restated Certificate of Incorporation on November 18, 2026, to effect a reverse stock split of its common stock. The split was previously approved by stockholders at the company’s 2026 Annual Meeting and subsequently ratified by the Board of Directors on October 26, 2026.

The reverse stock split is effective as of 5:00 p.m. Eastern Time on November 18, 2026. Under the terms of the amendment, every thirty-three (33) shares of common stock issued or outstanding were automatically reclassified into one new share of common stock. The par value of the common stock remains at $0.0001 per share, and the total number of authorized shares was not affected by the transaction.

The company stated that proportionate adjustments will be made to the exercise prices and the number of shares underlying outstanding equity awards and certain existing agreements. No fractional shares will be issued; holders who would have been entitled to a fractional share will have such share rounded up to the nearest whole share.

Trading of the company’s common stock on The Nasdaq Capital Market is expected to commence on a split-adjusted basis when the market opens on November 19, 2026. The trading symbol will remain “SNTI,” and the new CUSIP number for the post-split shares is 816944201.